Invention Grant
US08110578B2 Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
有权
吡嗪并[2,3-b]吡嗪mTOR激酶抑制剂用于肿瘤适应症和与mTOR / PI3K / Akt途径相关的疾病
![Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway](/docs/US/2012-02-07/US08110578B2/abs.jpg.600x600.jpg)
- Patent Title: Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
- Patent Title (中): 吡嗪并[2,3-b]吡嗪mTOR激酶抑制剂用于肿瘤适应症和与mTOR / PI3K / Akt途径相关的疾病
-
Application No.: US12605791Application Date: 2009-10-26
-
Publication No.: US08110578B2Publication Date: 2012-02-07
- Inventor: Sophie Perrin-Ninkovic , Roy L. Harris , John Sapienza , Graziella Shevlin , Patrick Papa , Branden Lee , Garrick Packard , Lida Tehrani , Jingjing Zhao , Jennifer Riggs , Jason Parnes , Deborah Mortensen , Weiming Xu , Loui Madakamutil , Kimberly Fultz , Rama K. Narla , Sabita Sankar , Jan Elsner
- Applicant: Sophie Perrin-Ninkovic , Roy L. Harris , John Sapienza , Graziella Shevlin , Patrick Papa , Branden Lee , Garrick Packard , Lida Tehrani , Jingjing Zhao , Jennifer Riggs , Jason Parnes , Deborah Mortensen , Weiming Xu , Loui Madakamutil , Kimberly Fultz , Rama K. Narla , Sabita Sankar , Jan Elsner
- Applicant Address: US CA San Diego
- Assignee: Signal Pharmaceuticals, LLC
- Current Assignee: Signal Pharmaceuticals, LLC
- Current Assignee Address: US CA San Diego
- Agency: Jones Day
- Main IPC: A61K31/497
- IPC: A61K31/497
![Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway](/abs-image/US/2012/02/07/US08110578B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
Public/Granted literature
- US20100216781A1 mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY Public/Granted day:2010-08-26
Information query
IPC分类:
